Developing standardized corticosteroid treatment for Duchenne muscular dystrophy

Contemporary Clinical Trials

Volumn 58, Issue , 2017, Pages 34-39

  Guglieri, Michela ^a   Bushby, Kate ^a   McDermott, Michael P ^b   Hart, Kimberly A ^b   Tawil, Rabi ^b   Martens, William B ^b   Herr, Barbara E ^b   McColl, Elaine ^c   Wilkinson, Jennifer ^c   Kirschner, Janbernd ^d   King, Wendy M ^b   Eagle, Michele ^a   Brown, Mary W ^b   Willis, Tracey ^e   Hirtz, Deborah ^f   Shieh, Perry B ^g   Straub, Volker ^a   Childs, Anne Marie ^h   Ciafaloni, Emma ^b   Butterfield, Russell J ⁱ   Horrocks, Iain ^j   Spinty, Stefan ^k   Flanigan, Kevin M ^l   Kuntz, Nancy L ^m   Baranello, Giovanni ⁿ   Roper, Helen ^o   Morrison, Leslie ^p   Mah, Jean K ^q   Manzur, Adnan Y ^r   McDonald, Craig M ^s   Schara, Ulrike ^t   von der Hagen, Maja ^u   Barohn, Richard J ^v   Campbell, Craig ^w   Darras, Basil T ^x   Finkel, Richard S ^y   Vita, Giuseppe ^z   Hughes, Imelda ^aa   Mongini, Tiziana ^ab   Pegoraro, Elena ^ac   Wicklund, Matthew ^ad   Wilichowski, Ekkehard ^ae   Bryan Burnette, W ^af   Howard, James F ^ag   McMillan, Hugh J ^ah   Thangarajh, Mathula ^ai   Griggs, Robert C ^b   more..

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF FREIBURG   (Germany)

^e ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL   (United Kingdom)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

ⁱ UNIVERSITY OF UTAH   (United States)

^j NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^k ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^l NATIONWIDE CHILDREN S HOSPITAL   (United States)

^m Ann and Robert H Lurie Children's Hospital   (United States)

ⁿ Neurological Institute Carlo Besta   (Germany)

^o BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^p University of Mexico   (Mexico)

^q UNIVERSITY OF CALGARY   (Canada)

^r UNIVERSITY COLLEGE LONDON   (United Kingdom)

^s UNIVERSITY OF CALIFORNIA   (United States)

^t UNIVERSITY OF DUISBURG ESSEN   (Germany)

^u DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^v UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^w LONDON HEALTH SCIENCES CENTRE   (Canada)

^x BOSTON CHILDREN S HOSPITAL   (United States)

^y NEMOURS CHILDREN S HOSPITAL   (United States)

^z UNIVERSITY OF MESSINA   (Italy)

^aa ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^ab UNIVERSITY OF TURIN   (Italy)

^ac UNIVERSITY OF PADOVA   (Italy)

^ad PENN STATE COLLEGE OF MEDICINE   (United States)

^ae UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^af MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^ag UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^ah CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^ai CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

more..

Author keywords

Deflazacort; Duchenne muscular dystrophy; Prednisolone; Randomized; Standards of care

Indexed keywords

DEFLAZACORT; PREDNISONE; IMMUNOSUPPRESSIVE AGENT; PREGNANE DERIVATIVE;

ARTICLE; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DATA ANALYSIS; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; GENOMICS; HUMAN; OSTEOLYSIS; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PRESCRIPTION; STANDARDIZATION; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; HEART FUNCTION TEST; JOINT CHARACTERISTICS AND FUNCTIONS; MALE; METHODOLOGY; MULTICENTER STUDY; MUSCLE STRENGTH; PATIENT SATISFACTION; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; VITAL CAPACITY;

CHILD; CHILD, PRESCHOOL; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HEART FUNCTION TESTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MUSCLE STRENGTH; MUSCULAR DYSTROPHY, DUCHENNE; PATIENT SATISFACTION; PREDNISONE; PREGNENEDIONES; RANGE OF MOTION, ARTICULAR; RESEARCH DESIGN; VITAL CAPACITY;

EID: 85018333312     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2017.04.008     Document Type: Article

References (41)

1. [1] Mendell, J.R., Shilling, C., Leslie, N.D. et al., Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann. Neurol. 71 (2012), 304–313.
2. [2] Brooke, M.H., Fenichel, G.M., Griggs, R.C. et al., Clinical investigation in Duchenne dystrophy: 2. Determination of the “power” of therapeutic trails based on the natural history. Muscle Nerve 6 (1983), 91–103.
3. [3] Brooke, M.H., Fenichel, G.M., Griggs, R.C. et al., Duchenne dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology 39 (1989), 475–481.
4. [4] Eagle, M., Baudouin, S.V., Chandler, C., Giddings, D.R., Bullock, R., Bushby, K., Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul. Disord. 12:10 (2003), 926–929.
5. [5] Eagle, M., Baudouin, S.V., Chandler, C. et al., Managing Duchenne muscular dystrophy – the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul. Disord. 17:6 (2007), 470–475.
6. [6] Bushby, K., Muntoni, F., Bourke, J.P., The management of cardiac complications in muscular dystrophy and myotonic dystrophy. Proceedings of 107th ENMC Workshop Neuromuscul. Disord., 13, 2003, 166–172.
7. [7] Bushby, K., Finkel, R., Birnkrant, D.J. et al., Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 9:1 (2010), 77–93 (Review).
8. [8] Bushby, K., Finkel, R., Birnkrant, D.J. et al., Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 9:2 (2010), 177–189 (Review).
9. [9] Manzur, A.Y., Kuntzer, T., Manzur, A.Y. et al., Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst. Rev., 1, 2008 Jan 23, CD003725.
10. [10] Bushby, K., Muntoni, F., Urtizberea, A., Hughes, R., Griggs, R., Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the uses of corticosteroids, 2–4 April 2004, Naarden, The Netherlands. Report on the 124th ENMC International Workshop Neuromuscular Disorders, 14, 2004, 526–534 8–9.
11. [11] Moxley, R.T., Ashwal, S., Pandya, S. et al., Corticosteroid treatment of Duchenne dystrophy [Report of the Quality standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society]. Neurology 64:1 (2005), 13–20.
12. [12] Biggar, W.D., Gingras, M., Fehlings, D.L., Harris, V.A., Steele, C.A., Deflazacort treatment of Duchenne muscular dystrophy. J. Pediatr. 138:1 (2001), 45–50.
13. [13] Biggar, W.D., Politano, L., Harris, V.A. et al., Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul. Disord. 14:8-9 (2004), 476–482.
14. [14] Bello, L., Gordish-Dressman, H., Morgenroth, L.P. et al., Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology 85:12 (2015), 1048–1055.
15. [15] Mazzone, E.S., Messina, S., Vasco, G. et al., Reliability of the North Star Ambulatory Assessment in a multicentric setting. Neuromuscul. Disord. 19:7 (2009), 458–461.
16. [16] Fenichel, G.M., Florence, J.M., Pestronk, A. et al., Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 41:12 (1991), 1874–1877.
17. [17] Fenichel, G.M., Mendell, J.R., Moxley, R.T. 3rd et al., A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch. Neurol. 48:6 (1991), 575–579.
18. [18] Griggs, R.C., Moxley, R.T. 3rd, Mendell, J.R. et al., Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch. Neurol. 48:4 (1991), 383–388.
19. [19] Sansome, A., Royston, P., Dubowitz, V., Steroids in Duchenne muscular dystrophy; pilot study of a new low-dosage schedule. Neuromuscul. Disord. 3:5–6 (1993), 567–569.
20. [20] Carter, G.T., McDonald, C.M., Preserving function in Duchenne dystrophy with long-term pulse prednisone therapy. Am. J. Phys. Med. Rehabil. 79 (2000), 455–458.
21. [21] Connolly, A.M., Schierbecker, J., Renna, R., Florence, J., High dose weekly oral prednisone improves strength in boys with Duchenne dystrophy. Neuromuscul. Disord. 12 (2002), 917–925.
22. [22] Dubowitz, V., Kinali, M., Main, M., Mercuri, E., Muntoni, F., Remission of clinical signs in early Duchenne dystrophy on intermittent low-dosage prednisolone therapy. Eur. J. Paediatr. Neurol. 6 (2002), 153–159.
23. [23] Kinali, M., Mercuri, E., Main, M., Muntoni, F., Dubowitz, V., An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromuscul. Disord. 12:Suppl. 1 (2002), S169–S174.
24. [24] Merlini, L., Cicognani, A., Malaspina, E. et al., Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve 27:2 (2003), 222–227.
25. [25] Escolar, D.M., Hache, L.P., Clemens, P.R. et al., Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 77 (2011), 444–452.
26. [26] Griggs, R.C., Herr, B.E., Reha, A. et al., Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve 48 (2013), 27–31.
27. [27] Landfeldt, E., Lindgren, P., Bell, C.F. et al., The burden of Duchenne muscular dystrophy: An international, cross-sectional study. Neurology 83:6 (2014), 529–536.
28. [28] Bladen, C.L., Rafferty, K., Straub, V. et al., The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Hum. Mutat. 34:11 (2013), 1449–1457.
29. [29] Heier, C.R., Damsker, J.M., Dillingham, B.C. et al., VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol. Med. 5 (2013), 1569–1585.
30. [30] Atkinson, M.J., Sinha, A., Hass, S.L. et al., Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual. Life Outcomes, 2(12), 2004.
31. [31] Phillips, M.F., Quinlivan, R.C., Edwards, R.H., Calverley, P.M., Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am. J. Respir. Crit. Care Med. 164:12 (2001), 2191–2194.
32. [32] Griggs, R.C., The use of pulmonary function testing as a quantitative measurement for therapeutic trials. Muscle Nerve 13:Suppl (1990), S30–S34.
33. [33] Tilley, B.C., Marler, J., Geller, N.L. et al., Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. Stroke 27 (1996), 2136–2142.
34. [34] Varni, J.W., Seid, M., Knight, T.S., Uzark, K., Szer, I.S., The PedsQL 4.0 Generic Core Scales: sensitivity, responsiveness, and impact on clinical decision-making. J. Behav. Med. 25:2 (2002), 175–193.
35. [35] Varni, J.W., Seid, M., Kurtin, P.S., PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med. Care 39:8 (2001), 800–812.
36. [36] Schafer, J.L., Analysis of Incomplete Multivariate Data. 1997, Chapman and Hall, London.
37. [37] O'Brien, P.C., Procedures for comparing samples with multiple endpoints. Biometrics 40:4 (1984), 1079–1087.
38. [38] Hopke, P.K., Liu, C., Rubin, D.B., Multiple imputation for multivariate data with missing and below-threshold measurements: time-series concentrations of pollutants in the artic. Biometrics 57:1 (2001), 22–33.
39. [39] Little, R.J.A., Rubin, D.B., Statistical Analysis with Missing Data. second ed., 2002, Wiley, New York.
40. [40] Mendell, J.R., Moxley, R.T. et al., Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N. Engl. J. Med. 320 (1989), 1592–1597.
41. [41] Peay, H.L., Scully, M.A., Cwik, V.A., Ciafaloni, E., Griggs, R.C., Can outcomes in Duchenne muscular dystrophy be improved by public reporting of data?. Neurology 80:6 (2013), 583–589.